Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:SLS 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

SELLAS Life Sciences (NASDAQ: SLS) shares doubled year-to-date in 2025, closing at $2.14 on Oct. 17 after a 38% after-hours jump and hitting a 52-week high of $2.27. BlackRock disclosed a 5.4% stake in the company. Interim Phase 3 trial results for SELLAS’s lead cancer drug showed median survival over 13.5 months in AML patients. Final trial data is expected by year-end 2025.
18 October 2025

Stock Market Today

  • Microsoft Stock Forecast: Potential to Reach $800 by 2030 Amid AI and Cloud Growth
    April 9, 2026, 8:18 AM EDT. Microsoft shares have dropped 22% year-to-date to around $369 but analysts see a 33% upside to $491 over the next year based on strong fundamentals and AI expansion. Q2 FY2026 results beat earnings estimates with revenue up 16.7% and Azure cloud growing 39%. A $625 billion commercial remaining performance obligation underpins multi-year revenue visibility. The bull case points to sustained Azure growth and OpenAI's $250 billion purchase commitment as key drivers for reaching $600+ targets. Bears caution on rising capital expenditures doubling to $29.8 billion, squeezing cash flow and AI-related losses increasing to $3.1 billion. Despite risks, the stock trades at a forward P/E of 19 with a BUY rating and 90% confidence from 24/7 Wall St. analysts, supporting a longer-term outlook potentially reaching $800 by 2030.

Latest article

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Jim Cramer Says Wednesday’s Rally Revealed What Stocks to Buy as Micron, Memory Names Stay in Focus

Jim Cramer Says Wednesday’s Rally Revealed What Stocks to Buy as Micron, Memory Names Stay in Focus

9 April 2026
U.S. stocks rebounded sharply Wednesday, with the Dow up over 1,300 points and chipmakers jumping 6.3% as investors responded to a tentative Middle East ceasefire. Jim Cramer pointed to gains in Sherwin-Williams, Caterpillar, Home Depot, and Goldman Sachs as signals of what institutions may favor if markets stabilize. Futures slipped Thursday as oil rose on renewed ceasefire doubts and investors awaited PCE inflation data.
Go toTop